In Q4, JNJ had an adjusted EPS of $1.86, slightly higher than the $1.82 per share expected. At the same time, the company generated revenues of $22.48 billion, while the market was looking for $21.67 billion.
Much of its revenue came from the pharmaceutical business, which produces the COVID-19 vaccine. The division reported revenues of $12.26 billion, 16% higher than that reported in Q4 2019.
For the future, Johnson & Johnson expects an adjusted EPS between $9.40-$9.60, and sales to reach a high of $91.7 billion. Moreover, as early as next week, the company is expected to publish data from Phase III of its COVID-19 vaccine trial.
Both US officials and Wall Street are looking forward to the vaccine to receive FDA’s approval. #JNJ’s vaccine requires just one dose to be administrated, unlike Moderna’s and Pfizer’s, which requires two doses.
Following the news, Johnson & Johnson stock price gained 2% in today’s premarket session.
Stay updated with the latest earning reports with CAPEX.com!